Sepsis and Coagulopathy: Clinical Trials

2 trials for Sepsis and Coagulopathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting, 1 withdrawn. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Withdrawn 1

Follow Sepsis and Coagulopathy: new trials by email Literature Review of Sepsis and Coagulopathy trials Research Report on Sepsis and Coagulopathy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sepsis-associated Thrombocytopenia and Platelet Transfusion (STAPT)
SAT patients - Sepsis, Sepsis and Coagulopathy
RecruitingNanfang Hospital, Southern Medical University15002025-11-152026-01-30
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
ART-123, Placebo Comparator - Placebo - Sepsis and Coagulopathy
Phase 3WithdrawnAsahi Kasei Pharma America Corporation2019-07-012019-09-13

Narrower conditions

Hemostatic Disorders (2)  ·  Sepsis (2)

Broader conditions

Cardiovascular Diseases (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Hemorrhagic Disorders (2)  ·  Infections (2)  ·  Inflammation (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Systemic Inflammatory Response Syndrome (2)  ·  Vascular Diseases (2)

Interventions

ART123 (1)

Sponsors

Asahi Kasei Pharma America Corporation (1)  ·  Nanfang Hospital, Southern Medical University (1)

Countries

China (1)

Top investigators

David Fineberg, MD (1)